Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)

November 13, 2023

Alkhouri et al. • 2023 • AASLD 2023 Congress